Celcuity https://validator.w3.org/feed/docs/rss2.html Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call Celcuity To Present at Upcoming Needham and Stifel Investor Conferences Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call Celcuity To Participate in Jefferies Global Healthcare Conference Celcuity Announces Pricing of Underwritten Common Stock Offering Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences Celcuity To Present at Upcoming Needham and Stifel Investor Conferences Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Senior Medical Director Senior Medical Director, Drug Safety and Pharmacovigilance Senior or Principal Scientist, Formulation and Process Development Senior Quality Assurance Auditor Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call Director or Senior Director, API Development Executive Director, Regulatory Affairs, Global Lab Systems Manager Senior Manager/Associate Director, Statistical Programming Senior Manager, Clinical Data Management Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program Associate Director, Process Engineering Associate Director, R&D Laboratory Associate Scientist, Cell Signaling and Assay Development Director, Medical Science Liaison, Carolinas Director, Medical Science Liaison, North Central (Chicago, Illinois) Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance Associate Director, Drug Safety and Pharmacovigilance Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”) Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer Block Pam. Unlock Tomorrow